When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CYTK - Cytokinetics' reldesemtiv flunks ALS study; shares down 15% premarket
Cytokinetics Incorporated
Cytokinetics (NASDAQ:CYTK) slumps 15% premarket on light volume in reaction to unsuccessful results from a Phase 2 clinical trial, FORTITUDE-ALS, evaluating reldesemtiv (CK-2127107) in patients with amyotrophic lateral sclerosis (ALS).
More news on: Cytokinetics, Incorporated, Astellas Pharma Inc., Astellas Pharma Inc., Healthcare stocks news, Stocks on the move,